5-Alpha-Reductase Deficiency Clinical Presentation

  • Author: Jill E Emerick, MD; Chief Editor: Stephen Kemp, MD, PhD   more...
 
Updated: Jul 29, 2010
 

History

Diagnosis of 5-alpha-reductase type 2 deficiency (5-ARD) is usually made in the newborn period when the infant presents with ambiguous genitalia.[7] No risk factors or clinical markers in pregnancy are known. Genital ambiguity is occasionally diagnosed prenatally when an infant who is demonstrated by amniocentesis or chorionic villus sampling to have XY karyotype fails to have a demonstrable penis on ultrasonography.

If 5-alpha-reductase deficiency is considered in a newborn, a broad approach to ambiguous genitalia should be taken.[1, 6] The utmost care should be taken not to assign a gender to the child before evaluation and consultation with an experienced, multidisciplinary team. The first words spoken to the parents are likely to be remembered and should focus on the overall health of the infant. A sensitive discussion about the uncertainty of the child's gender and explanation of the child's genital anatomy can be aided by online developmental Web sites, such as the ones available on the Sick Kids and DSD Guidelines sites. See Ambiguous Genitalia and Intersexuality for more in depth discussion

Initial evaluation should begin with a careful history.[1] Assess prenatal and maternal past medical and family history. Specific questions should be asked regarding relatives with disorders of sexual development (DSDs), neonatal deaths, amenorrhea, or infertility and consanguinity. Parental consanguinity increases the child's risk for autosomal recessive disorders including 5-alpha reductase type 2 deficiency.

Next

Physical

Workup of ambiguous genitalia must include careful physical examination to characterize the degree of virilization on the Prader scale (see the image below), presence of palpable gonadal tissue, and overall health of the child.[6]

Prader scale reflecting the degree of virilizationPrader scale reflecting the degree of virilization of the external genitalia. The internal genitalia reflect the changes in the urogenital sinus in response to the presence or absence of mullerian inhibiting hormone (MIH)

Neonatal presentation

Phenotypic findings in a newborn are limited to the genitalia.[7, 8] The spectrum of findings ranges from minimal undervirilization presenting with normal male anatomy, except for isolated micropenis or hypospadias, to severe undervirilization presenting as normal female external genitalia with mild clitoral enlargement as the only physical finding.

Most commonly, the external genitalia exhibit labial appearance to the labioscrotal folds with some mild rugation or pigmentation present in some patients.

The phallus is indeterminate in size. Its length falls between 1 cm (ie, usual maximum for a clitoris) and 2 cm (ie, lower limit of normal for a penis).

The urethra may empty anywhere from the tip of the phallus to the perineum, with the latter observed more often.

The testes are usually in the inguinal canals bilaterally; however, in some individuals with 5-alpha-reductase type 2 deficiency, the testes can be found in the labioscrotal folds or retained in the abdomen.

A pseudovaginal blind-ending introitus is usually present with a normal hymen.

Because the uterus is absent, rectal examination results are negative for a cervical mass.

The rest of the examination findings are within normal limits.

Presentation of males at puberty

Clear signs of virilization predominate at this age. The escutcheon is male in distribution. The phallus exhibits definite enlargement. The shoulders are relatively broad and the hips are narrow.

Muscularity and body hair may increase. No breast development is generally present. A prominent Adam's apple may start to develop. Facial hair develops. The child's voice may begin to deepen.

The mucosa of the vaginal introitus remains atrophic in appearance (remaining red) rather than the thickened pink of estrogen-stimulated mucosa.

Presentation of females

Females homozygous for 5-alpha-reductase type 2 deficiency have very subtle manifestations, such as delayed menarche, minimal acne, and minimal body hair.[9] Fertility is normal in females.

Previous
Next

Causes

The cause of 5-alpha-reductase type 2 deficiency is the deficiency of the type 2 isozyme of 5-alpha-reductase.

As with most single enzyme disorders, 5-alpha-reductase type 2 deficiency is an autosomal recessive trait and sex limited because the clinical syndrome only affects genetic males, with very subtle phenotypic findings in homozygous females.[10]

Previous
 
 
Contributor Information and Disclosures
Author

Jill E Emerick, MD  Fellow, Pediatric Endocrinology, Uniformed Services University of the Health Sciences, Pediatrics Department, Walter Reed Army Medical Center/National Naval Medical Center

Jill E Emerick, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Noelle Summers Larson, MD  Fellow, Pediatric Endocrinology, Uniformed Services University of the Health Sciences, Pediatrics Department, Walter Reed Army Medical Center/National Naval Medical Center

Noelle Summers Larson, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Medical Association, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Andrew J Bauer, MD  Program Director, Pediatric Endocrinology Fellowship, Uniformed Services University of the Health Sciences

Andrew J Bauer, MD is a member of the following medical societies: American Academy of Pediatrics, American Thyroid Association, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Phyllis W Speiser, MD  Chief, Division of Pediatric Endocrinology, The Children's Hospital, North Shore LIJ Health System; Professor of Pediatrics, New York University School of Medicine

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Barry B Bercu, MD  Professor, Departments of Pediatrics, Molecular Pharmacology and Physiology, University of South Florida College of Medicine, All Children's Hospital

Barry B Bercu, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Federation for Clinical Research, American Medical Association, American Pediatric Society, Association of Clinical Scientists, Endocrine Society, Florida Medical Association, Lawson-Wilkins Pediatric Endocrine Society, Pituitary Society, Society for Pediatric Research, Society for the Study of Reproduction, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD  Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. [Guideline] Houk CP, Lee PA. Consensus statement on terminology and management: disorders of sex development. Sex Dev. 2008;2(4-5):172-80. [Medline].

  2. Silver RI, Russell DW. 5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias. J Urol. Sep 1999;162(3 Pt 2):1142-5. [Medline].

  3. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. Dec 30 2002;198(1-2):51-9. [Medline].

  4. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. Feb 2009;1155:43-56. [Medline].

  5. Medonca BB, Domenice S, Arnhold, JP, and Costa EMF. 46, XY disorders of sex development (DSD). Clinical Endocrinology. 2009;70:173-187.

  6. Allen L. Disorders of Sexual Development. Obstet Gynecol Clin N Am. 2009;36:25-45.

  7. Bertelloni S, Scaramuzzo RT, Parrini D, Baldinotti F, Tumini S, Ghirri P. Early diagnosis of 5alpha-reductase deficiency in newborns. Sex Dev. 2007;1(3):147-51. [Medline].

  8. Praveen EP, Desai AK, Khurana ML, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab. Feb 2008;21(2):173-9. [Medline].

  9. Katz MD, Cai LQ, Zhu YS, et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab. Nov 1995;80(11):3160-7. [Medline].

  10. Choi JH, Kim GH, Seo EJ, Kim KS, Kim SH, Yoo HW. Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development. J Pediatr Endocrinol Metab. Jun 2008;21(6):545-53. [Medline].

  11. hCG Stimulation Test v2. Available at www.dvh.nhs.uk/downloads/documents/5K1WT1DN2U_hCG_Stimulation_Test_v2.pdf. Accessed 11/09/2009.

  12. Informed Consent for Pediatric Genitoplasty or Gonadectomy in Patients with DSDs. AIC Legal. Available at http://www.lgbtbar.org/annual/CLE_materials/3B/GuidelinesforInformedConsent.pdf. Accessed 11/04/2009.

  13. Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore). Mar 1996;75(2):64-76. [Medline].

  14. Price P, Wass JA, Griffin JE, et al. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha- reductase deficiency and disorders of the androgen receptor. J Clin Invest. Oct 1984;74(4):1496-508. [Medline].

  15. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab. Aug 2006;91(8):3017-23. [Medline].

  16. Sharma S, K Gupta D. Male genitoplasty for intersex disorders. Adv Urol. 2008;685897. [Medline].

  17. Ghanem H, Shamloul R, Khodeir F, ElShafie H, Kaddah A, Ismail I. Structured management and counseling for patients with a complaint of a small penis. J Sex Med. Sep 2007;4(5):1322-7. [Medline].

  18. Vardi Y, Har-Shai Y, Gil T, Gruenwald I. A critical analysis of penile enhancement procedures for patients with normal penile size: surgical techniques, success, and complications. Eur Urol. Nov 2008;54(5):1042-50. [Medline].

  19. Katz MD, Kligman I, Cai LQ, et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med. Apr 3 1997;336(14):994-7. [Medline].

  20. Wilson BE, Reiner WG. Management of intersex: a shifting paradigm. J Clin Ethics. Winter 1998;9(4):360-9. [Medline].

  21. Tamar-Mattis A. Medical decision making adn the child with a DSD. www.endocrinetoday.com. Available at http://www.endocrinetoday.com/view.aspx?rid=32542. Accessed 11/05/2009.

  22. Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. Aug 2005;34(4):399-410. [Medline].

  23. hCG Stimulation Test. Available at www.dvh.nhs.uk/downloads/documents/5K1WT1DN2U_hCG_Stimulation_Test_v2.pdf. Accessed 11/09/2009.

Previous
Next
 
Biochemical effects of 5-alpha-reductase type 2 deficiency in testosterone biosynthesis. Typically levels of testosterone are elevated, whereas levels of dihydrotestosterone (DHT) are significantly decreased, leading to male undervirilization.
Prader scale reflecting the degree of virilization of the external genitalia. The internal genitalia reflect the changes in the urogenital sinus in response to the presence or absence of mullerian inhibiting hormone (MIH)
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.